Usually used to lower blood sugar levels in individuals with type-2 diabetes, Ozempic is back on the lips of medical experts ...

GLP-1: Glucagon-like peptide-1 ... of data indicating improved A1c and fasting plasma glucose and decreased side-effect profile compared with standard GLP1-RA preparations. Multiple prospective ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists ... has an adaptive effect on the muscles ...

The PRAC still has another safety review on the go for the GLP-1 ... side effects that can be caused by Ozempic and Mounjaro (tirzepatide), Lilly’s dual GLP-1/GIP agonist.

UK MHRA reminds healthcare professionals to advise patients of the side effects of GLP-1 agonists and to report misuse: United Kingdom Monday, October 28, 2024, 17:00 Hrs [IST] Th ...

A recent commentary published in The Lancet journal highlights the critical importance of skeletal muscle mass in the context ...

For the first time in decades, the prevalence of obesity has not increased in the USA, according to the latest National Health and Nutrition Examination Survey from the US Centers for Disease Control ...

In this webinar, you’ll learn about GLP-1 agonists that can help with obesity treatment, common side effects of these drugs, misunderstandings about their use, and more. About the expert ...

Most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...